Agenus Inc. — Q1 2017 Form 10-Q
Reporting period: Three months ended March 31, 2017. Agenus is a clinical-stage immuno-oncology company developing antibody therapies, cancer vaccines and vaccine adjuvants. Its programs are largely dependent on clinical progress and collaboration partners.
Financial performance and liquidity
| Metric | Q1 2017 | Q1 2016 / prior period |
|---|---|---|
| Revenue | $27.0 million | $6.0 million |
| Research and development expense | $32.6 million | $25.0 million |
| General and administrative expense | $7.8 million | $9.2 million |
| Operating loss | $13.3 million | $28.0 million |
| Net loss | $17.1 million; $0.18 per share | $31.8 million; $0.37 per share |
| Cash used in operating activities | $14.8 million | $21.5 million |
- Cash, cash equivalents and short-term investments totaled $123.8 million at quarter-end, up $47.4 million from December 31, 2016. Cash and cash equivalents alone were $113.9 million.
- Financing activities provided $62.1 million, primarily reflecting $61.8 million of net equity proceeds. Cash increased by $42.4 million during the quarter.
- Debt principal was $114.1 million; the balance-sheet carrying amount was approximately $134.3 million, including accrued non-cash interest and net discounts. Net interest expense was $4.6 million.
- Accumulated deficit was $923.6 million. Stockholders’ equity was $8.9 million at March 31, compared with a $39.1 million deficit at December 31, 2016.
- Gross margin is not presented as a clear value in the filing; revenue is primarily collaboration-related, and the company reports operating expenses by category.
Material changes and business developments
- Revenue rose sharply, principally due to a $20.0 million accelerated Incyte milestone payment recognized in Q1 and higher Incyte development-cost reimbursements. The milestone is a significant non-recurring contributor to the period’s revenue.
- R&D expense increased 30%, mainly from higher third-party program costs and milestone and license fees. G&A expense declined 16%, primarily because Q1 2016 included a performance-based share-compensation charge.
- Under a February amendment, Incyte assumed global development, manufacturing and commercialization costs and responsibility for GITR and OX40; Agenus became eligible for a 15% royalty on global net sales if products are approved. The amendment also provides for up to $510.0 million in potential future milestones across collaboration programs, subject to achievement.
- Incyte separately bought 10 million Agenus shares for $6.00 per share, or $60.0 million gross, and owned approximately 18.1% of the company immediately after the transaction. The issuance increased dilution.
- Agenus extended the 2015 subordinated notes’ maturity from February 2018 to February 2020; the notes have $14.0 million principal and 8% annual interest.
Outlook, risks and contingencies
- Management expects current cash and short-term investments to fund liquidity needs through the first half of 2018, and expects to seek additional funding before resources are depleted. The filing also says resources should cover more than one year from issuance; the more specific MD&A estimate is through the first half of 2018.
- The company expects significant losses to continue as it funds research, clinical trials and regulatory work. It may pursue partnerships, asset sales, debt or equity financing, and may reduce spending or operations if needed. No specific financial guidance is provided.
- GSK’s shingles and malaria vaccine candidates, which use Agenus’s QS-21 adjuvant, had regulatory filings underway; first products containing QS-21 were anticipated in 2018, subject to approval. Royalties from these products are committed to servicing the royalty-backed notes.
- Clinical and commercial outcomes remain uncertain: antibody programs are early stage, and Agenus relies on partners for development, manufacturing, regulatory approval and commercialization. Key risks include trial failure or delay, financing needs, competition, manufacturing and operational transitions, foreign-exchange exposure, and intellectual-property challenges.
- The company reported no off-balance-sheet arrangements and stated that disclosure controls were effective, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- How much of future revenue and runway depends on one-time milestones, partner reimbursements, or new financing, given the $20.0 million Incyte payment and management’s first-half-2018 liquidity estimate.
- Progress, funding responsibility and decision rights under the amended Incyte agreement, including whether clinical or commercial milestones and royalties are achieved.
- Terms, cash-flow implications and royalty security of the $100.0 million royalty-backed notes, including potential put, make-whole and default obligations.
- Clinical progress and timing for the antibody, Prophage and AutoSynVax programs, and the status of GSK regulatory reviews and anticipated launches.
- Potential share dilution from the Incyte issuance, equity plans, warrants, options and other registered shares available for sale.